Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions

In this podcast episode, Suzanne Lentzsch, MD, PhD, and  Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:

• Selecting optimal triplet regimen after first relapse
• Sequencing treatment options after multiple relapses
• Managing patient expectations when selecting treatments
• Emerging treatment options for R/R MM

Presenters:  

Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Saad Z. Usmani, MD, MBA, FACP
Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina

Supported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.

Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3gjr62p

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.